Literature DB >> 7769094

Tissue plasminogen activator (tPA) inhibits plasmin degradation of fibrin. A mechanism that slows tPA-mediated fibrinolysis but does not require alpha 2-antiplasmin or leakage of intrinsic plasminogen.

J H Wu1, S L Diamond.   

Abstract

Thrombolysis is dramatically slower when high concentrations of lytic agent are used. This paradoxical observation, first described as "plasminogen steal," was originally believed to be due to depletion of extrinsic plasminogen and consequent leaching of clot-bound plasminogen. We report that administration of increasing concentrations of recombinant human tissue plasminogen activator (tPA) to fibrin gels resulted in lysis rates that displayed a maximum, with significantly slower rates found at higher tPA, regardless of whether plasminogen was supplied extrinsically or intrinsically. A similar maximum in lysis rates was observed in a system lacking an extrinsic phase when plasminogen was added to fibrin suspensions preincubated with increasing tPA. Thus, intrinsic plasminogen leakage and alpha 2-antiplasmin were not required for the decreased lysis at high tPA. No maximum was observed for increasing concentrations of urokinase. Using fibrin suspensions or gels preincubated with tPA before addition of plasmin, we report that tPA, but not urokinase, caused a dose-dependent inhibition of the fibronolytic action of plasmin. With respect to optimal dosage schemes and the design of novel lytic agents, these findings indicate that (a) there exists a biochemical mechanism against minimizing reperfusion time with increasing tPA dosages and (b) the fibrin affinity of tPA may cause reduced fibrinolysis by plasmin.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7769094      PMCID: PMC295930          DOI: 10.1172/JCI117949

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  31 in total

1.  Amino acid sequence studies on plasmin-derived fragments of human fibrinogen: amino-terminal sequences of intermediate and terminal fragments.

Authors:  T Takagi; R F Doolittle
Journal:  Biochemistry       Date:  1975-03-11       Impact factor: 3.162

2.  Mass-length ratio of fibrin fibers from gel permeation and light scattering.

Authors:  M E Carr; L L Shen; J Hermans
Journal:  Biopolymers       Date:  1977-01       Impact factor: 2.505

3.  Fibrin suspension as a substrate fop plasmin: determination and kinetics.

Authors:  S Kanai; H Okamoto; Y Tamaura; S Yamazaki; Y Inada
Journal:  Thromb Haemost       Date:  1979-12-21       Impact factor: 5.249

4.  The sequence gamma-(312-324) is a fibrin-specific epitope.

Authors:  W J Schielen; H P Adams; K van Leuven; M Voskuilen; G I Tesser; W Nieuwenhuizen
Journal:  Blood       Date:  1991-05-15       Impact factor: 22.113

5.  The effect of plasmin on the subunit structure of human fibrinogen.

Authors:  S V Pizzo; M L Schwartz; R L Hill; P A McKee
Journal:  J Biol Chem       Date:  1972-02-10       Impact factor: 5.157

Review 6.  Assay of coagulation proteases using peptide chromogenic and fluorogenic substrates.

Authors:  R Lottenberg; U Christensen; C M Jackson; P L Coleman
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

7.  Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli.

Authors:  D Pennica; W E Holmes; W J Kohr; R N Harkins; G A Vehar; C A Ward; W F Bennett; E Yelverton; P H Seeburg; H L Heyneker; D V Goeddel; D Collen
Journal:  Nature       Date:  1983-01-20       Impact factor: 49.962

8.  The binding of human plasminogen to fibrin and fibrinogen.

Authors:  M A Lucas; L J Fretto; P A McKee
Journal:  J Biol Chem       Date:  1983-04-10       Impact factor: 5.157

9.  Initial plasmin-degradation of fibrin as the basis of a positive feed-back mechanism in fibrinolysis.

Authors:  E Suenson; O Lützen; S Thorsen
Journal:  Eur J Biochem       Date:  1984-05-02

10.  Tissue plasminogen activator and urokinase mediate the binding of Glu-plasminogen to plasma fibrin I. Evidence for new binding sites in plasmin-degraded fibrin I.

Authors:  P C Harpel; T S Chang; E Verderber
Journal:  J Biol Chem       Date:  1985-04-10       Impact factor: 5.157

View more
  4 in total

1.  The interplay between tissue plasminogen activator domains and fibrin structures in the regulation of fibrinolysis: kinetic and microscopic studies.

Authors:  Colin Longstaff; Craig Thelwell; Stella C Williams; Marta M C G Silva; László Szabó; Krasimir Kolev
Journal:  Blood       Date:  2010-10-21       Impact factor: 22.113

Review 2.  Targeting therapeutics across the blood brain barrier (BBB), prerequisite towards thrombolytic therapy for cerebrovascular disorders-an overview and advancements.

Authors:  K K Pulicherla; Mahendra Kumar Verma
Journal:  AAPS PharmSciTech       Date:  2015-01-23       Impact factor: 3.246

3.  Breaking the fibrinolytic speed limit with microwheel co-delivery of tissue plasminogen activator and plasminogen.

Authors:  Dante Disharoon; Brian G Trewyn; Paco S Herson; David W M Marr; Keith B Neeves
Journal:  J Thromb Haemost       Date:  2021-12-19       Impact factor: 5.824

4.  Efficacy of Sonothrombolysis Using Microbubbles Produced by a Catheter-Based Microfluidic Device in a Rat Model of Ischemic Stroke.

Authors:  Adam J Dixon; Jun Li; John-Marschner Robert Rickel; Alexander L Klibanov; Zhiyi Zuo; John A Hossack
Journal:  Ann Biomed Eng       Date:  2019-01-28       Impact factor: 3.934

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.